207_Combined course Presentations
Trials with Cetuximab in anal cancer
Trial
N of patients
IMRT Regimen
Toxicity Efficacy
ECOG 3205 61
some 5-FU/CisP +RT + cetuximab
32% G4 5% G5 26% G4 4% G5
The 3- year LRF 23%
AMC045 HIV+
45
some NACT + 5- FU/CisP +RT + cetuximab
LRF 16%
Garg MK, et al., J Clin Oncol. 2017 Jan 9: [Epub ahead of print] Garg MK, et al., J Clin Oncol 34, 2016 (suppl; abstr 3522)
Made with FlippingBook